BMC
TEVA icon

Bear Mountain Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Bear Mountain Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$223 Hold
7
– – ﹤0.01% 190
2026
Q1 		$224 Hold
7
– – ﹤0.01% 173
2025
Q4 		$226 Hold
7
– – ﹤0.01% 175
2025
Q3 		$133 Buy
+7
New +$123 ﹤0.01% 299

Other funds holding TEVA

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
UBP
Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
SBCM
Silverberg Bernstein Capital Management Armonk, New York $261M AUM 89.93% 1-Year Est. Return

Bear Mountain Capital's TEVA Position: Q2 2026 in Review

Bear Mountain Capital held its Teva Pharmaceuticals (TEVA) position steady in Q2 2026 at 7 shares worth $223. The position accounts for ﹤0.01% of the portfolio, ranked #190.

Bear Mountain Capital first reported a position in TEVA in Q3 2025 and has held it in 4 quarters since. The position peaked at $226 in Q4 2025. 89 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Bear Mountain Capital held 7 shares of Teva Pharmaceuticals worth $223 as of Q2 2026.
  • Bear Mountain Capital left its Teva Pharmaceuticals share count unchanged in Q2 2026.
  • Teva Pharmaceuticals made up ﹤0.01% of Bear Mountain Capital's portfolio in Q2 2026, its #190 holding.
  • Bear Mountain Capital first reported a position in Teva Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Bear Mountain Capital's Teva Pharmaceuticals position peaked at $226 in Q4 2025.
  • 89 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Bear Mountain Capital's 13F filing for Q2 2026, filed 20 Jul 2026.